Ketamine-assisted psychotherapy treatment of chronic pain and comorbid depression: a pilot study of two approaches

被引:0
|
作者
Batievsky, Daniella [1 ]
Weiner, Michelle [2 ]
Kaplan, Shari B. [3 ]
Thase, Michael Edward [4 ,5 ]
Maglione, Domenick Nicholas [6 ]
Vidot, Denise Christina [6 ]
机构
[1] Univ Penn, Dept Psychol, Philadelphia, PA 19104 USA
[2] Spine & Wellness Ctr Amer, Miami, FL USA
[3] Cannectd Wellness, Boca Raton, FL USA
[4] Perelman Sch Med, Dept Psychiat, Philadelphia, PA USA
[5] United States Dept Vet Affairs, Corporal Michael J Crescenz VA Med Ctr, Philadelphia, PA USA
[6] Univ Miami, Sch Nursing & Hlth Studies, Coral Gables, FL USA
来源
FRONTIERS IN PAIN RESEARCH | 2023年 / 4卷
关键词
ketamine; depression; pain; intramuscular; therapy; microdose; psychedelic; psycholytic; ANTIDEPRESSANT; QUESTIONNAIRE; TRIAL;
D O I
10.3389/fpain.2023.1127863
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Chronic pain and depression diagnoses are skyrocketing. There is an urgent need for more effective treatments. Ketamine was recently established to alleviate pain and depression, but many gaps remain in the scientific literature. This paper reports the findings of an observational preliminary study that explored the efficacy of ketamine-assisted psychotherapy (KAPT) for chronic pain/major depressive disorder (MDD) comorbidity. Researchers evaluated two KAPT approaches to determine optimal route of administration/dose. Ten individuals diagnosed with a chronic pain disorder and MDD receiving KAPT were recruited: five individuals pursuing the psychedelic approach (high doses administered intramuscularly 24 h before therapy) and five individuals pursuing the psycholytic approach (low doses administered sublingually via oral lozenges during therapy). To evaluate differences between altered states of consciousness each approach induces, participants completed the Mystical Experience Questionnaire (MEQ30) after their first (T-1), third (T-2) and sixth/final (T-3) treatment sessions. Primary outcomes were change in Beck Depression Inventory (BDI) scores and Brief Pain Inventory (BPI) Short Form scores from baseline (T0) to (T-1)-(T-3). Secondary outcomes were changes in Generalized Anxiety Disorder (GAD-7) Scale scores and Post-Traumatic Stress Disorder Checklist (PCL-5) scores at each timepoint. Statistically significant differences between each approach were not observed, but the small sample's limited statistical power makes changes seen worth noting. All participants' symptoms declined throughout treatment. Psychedelic treatment participants saw a larger, more consistent decrease. Researchers conclude that KAPT may be effective for treating chronic pain/MDD comorbidity, anxiety and Post-Traumatic Stress Disorder (PTSD). Findings imply that the psychedelic approach may be more effective. This pilot study serves as a basis for more extensive research that will inform how clinicians administer treatment to optimize outcomes.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Effects of Embodiment in Virtual Reality for Treatment of Chronic Pain: Pilot Open-Label Study
    Saby, Adam
    Alvarez, Anthony
    Smolins, David
    Petros, James
    Nguyen, Lincoln
    Trujillo, Michael
    Aygun, Oytun
    JMIR FORMATIVE RESEARCH, 2024, 8
  • [42] Acupuncture for comorbid mild-moderate depression and chronic musculoskeletal pain: study protocol for a randomized controlled trial
    Sheng Li
    Jing Liu
    Jianpeng Huang
    Ding Luo
    Qian Wu
    Baile Ning
    Ling Chen
    Jianhua Liu
    Wen-Bin Fu
    Trials, 22
  • [43] An exploratory study of changes in salivary cortisol, depression, and pain intensity after treatment for chronic pain
    Evans, Kimberly David
    Douglas, Bill
    Bruce, Neville
    Drummond, Peter D.
    PAIN MEDICINE, 2008, 9 (06) : 752 - 758
  • [44] Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study
    Carr, DB
    Goudas, LC
    Denman, WT
    Brookoff, D
    Staats, PS
    Brennen, L
    Green, G
    Albin, R
    Hamilton, D
    Rogers, MC
    Firestone, L
    Lavin, PT
    Mermelstein, F
    PAIN, 2004, 108 (1-2) : 17 - 27
  • [45] Pilot Randomized Trial of Collaborative Behavioral Treatment for Chronic Pain and Depression in Persons Living with HIV/AIDS
    Lisa A. Uebelacker
    Risa B. Weisberg
    Debra S. Herman
    Genie L. Bailey
    Megan M. Pinkston-Camp
    Sarah L. Garnaat
    Michael D. Stein
    AIDS and Behavior, 2016, 20 : 1675 - 1681
  • [46] Lipidomic Signatures Informs Intravenous Racemic Ketamine Associated Remission in Treatment-Resistant Depression: A Pilot Study
    Singh, Balwinder
    MahmoudianDehkordi, Siamak
    Voort, Jennifer Vande
    Han, Xianlin
    Port, John
    Frye, Mark
    Daouk, Rima Kaddurah
    NEUROPSYCHOPHARMACOLOGY, 2022, 47 : 192 - 192
  • [47] Lipidomic Signatures Informs Intravenous Racemic Ketamine Associated Remission in Treatment-Resistant Depression: A Pilot Study
    Singh, Balwinder
    MahmoudianDehkordi, Siamak
    Vande Voort, Jennifer
    Han, Xianlin
    Port, John
    Frye, Mark
    Daouk, Rima Kaddurah
    NEUROPSYCHOPHARMACOLOGY, 2022, 47 (SUPPL 1) : 192 - 192
  • [48] Exploring the use of Vibroacoustic treatment for managing chronic pain and comorbid mood disorders: A mixed methods study
    Campbell, Elsa A.
    Hynynen, Jouko
    Burger, Birgitta
    Ala-Ruona, Esa
    NORDIC JOURNAL OF MUSIC THERAPY, 2019, 28 (04) : 291 - 314
  • [49] Transient effects of multi-infusion ketamine augmentation on treatment-resistant depressive symptoms in patients with treatment-resistant bipolar depression - An open-label three-week pilot study
    Zhuo, Chuanjun
    Ji, Feng
    Tian, Hongjun
    Wang, Lina
    Jia, Feng
    Jiang, Deguo
    Chen, Ce
    Zhou, Chunhua
    Lin, Xiaodong
    Zhu, Jingjing
    BRAIN AND BEHAVIOR, 2020, 10 (08):
  • [50] PRELIMINARY FEASIBILITY OF A NOVEL MEDICATION-ASSISTED PSYCHOTHERAPY: KETAMINE ENHANCED RADICALLY OPEN DIALECTICAL BEHAVIOR THERAPY (RO DBT) FOR TREATMENT RESISTANT DEPRESSION
    Gilbert, Kirsten
    Xie, Jason
    Steinhoff, Molly
    Farber, Nuri B.
    NEUROPSYCHOPHARMACOLOGY, 2024, 49 : 468 - 468